Last checked at 13 Dec 2023 17:07
UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision
UK economy shrinks by 0.3% in October
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades5,381
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,106.00
Bid:
12,118.00
Ask:
12,122.00
Change:
86.00 (0.72%)
Spread:
4.00 (0.033%)
Open:
12,062.00
High:
12,182.00
Low:
12,032.00
Prev. Close:
12,020.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Astrazeneca to gain rights to Almirall's respiratory franchise
Wed, 30th Jul 2014 08:16
Astrazeneca has struck a deal with drug developer Almirall for the rights to the Spanish group's respiratory franchise. Under the agreement, which includes an initial consideration of $875m, the FTSE 100-listed company will gain the rights for the development and commercialisation of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational novel therapies.Astra will make further payments of up to $1.22bn based on development, launch, and sales-related milestones. The Anglo-Swedish drugs giant has also agreed to make various sales-related payments. The franchise includes Eklira, which according to Almirall's first half results has grown 50% to €58.0m, equal to 14.4% of the company's total sales. The product has achieved increased market share in all of its key geographies. The respiratory franchise generated sales of €123.5m, up 13.6% compared to the first half of 2013. "The business combination will give Astrazeneca immediate access to on-market revenues, contributing to the company's return to growth," it said. It expects the transaction to be neutral to core earnings per share in 2015 and accretive from 2016, with no impact on 2014. The group said it planned to finance the transaction from existing cash resources and short-term credit facilities.Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, will also transfer to Astrazeneca.The group's Chief Executive Officer, Pascal Soriot, said: "Our agreement with Almirall brings strategic and long-term value to AstraZeneca's strong respiratory franchise, one of our key growth platforms. We will benefit from immediate and growing product revenues which we anticipate will be rapidly accretive to earnings. "Chronic respiratory disease affects hundreds of millions of people around the world. By combining our innovative portfolios and leveraging AstraZeneca's global scientific and commercial capabilities, we will strengthen our ability to address the entire spectrum of care in asthma and COPD." Shares in Astrazeneca were up 1.1% to 4,370.5p at 08:16 on Wednesday.NR
More News
12 Dec 2023 16:00
London close: Stocks slip as investors digest US inflation
(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.
Read more12 Dec 2023 12:07
London midday: FTSE still firmer ahead of US inflation print
(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:53
LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI
(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.
Read more12 Dec 2023 08:37
AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion
(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:16
AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.
Read more12 Dec 2023 02:00
UK companies pause China investment decisions as economy slows, survey shows
BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.
Read more11 Dec 2023 08:15
AstraZeneca says danicopan tests well as blood disorder treatment
(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more1 Dec 2023 08:52
LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI
(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.
Read more1 Dec 2023 08:33
AstraZeneca discontinues two phase III evidence trials for Lokelma
(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.
Read more1 Dec 2023 08:01
AstraZeneca calls off two phase III trials into hyperkalaemia treatment
(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.
Read more1 Dec 2023 07:41
LONDON BRIEFING: Stocks called higher; UK house prices fall annually
(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.
Read more